David Matson
About David Matson
David Matson is a Principal Scientist at Fulcrum Therapeutics in Cambridge, Massachusetts, with a background in Biology and Research, Measurement, and Statistics. He has over 16 years of experience in therapeutic areas such as pain management and anxiolytics, and he actively contributes to project strategy and biology elucidation on cross-functional teams.
Work at Fulcrum Therapeutics
David Matson has been serving as Principal Scientist at Fulcrum Therapeutics since 2020. In this role, he is involved in guiding project strategy and elucidating biology as the in vivo core team representative on several cross-functional teams. His contributions focus on therapeutic areas that include acute, chronic, and neuropathic pain, as well as anxiolytics and hypnotics. His work supports the company's mission to develop innovative therapies.
Education and Expertise
David Matson earned a Bachelor of Science in Biology from Syracuse University, where he studied from 1992 to 1996. He later obtained a Master of Science in Research, Measurement, and Statistics from Southern Connecticut State University, completing his studies in 2004. His educational background provides a strong foundation for his extensive experience in therapeutic areas, particularly in pain management and related fields.
Background
Before joining Fulcrum Therapeutics, David Matson worked at Amgen for 12 years, from 2008 to 2020, where he held the position of Scientist. His experience at Amgen contributed to his expertise in various therapeutic areas, enhancing his skills in in vivo, ex vivo, and in vitro techniques. This background has equipped him with a versatile skill set applicable to his current role.
Professional Experience
David Matson has extensive experience in the pharmaceutical industry, particularly in therapeutic areas such as acute, chronic, and neuropathic pain, as well as anxiolytics and hypnotics. His role at Fulcrum Therapeutics involves collaboration with cross-functional teams, where he plays a key part in project strategy and biological insights. His professional journey reflects a commitment to advancing therapeutic solutions.